Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EPS without NRI Growth Rate was -0.90% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -24.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Ionis Pharmaceuticals was 69.40% per year. The lowest was -152.00% per year. And the median was -0.90% per year.
Ionis Pharmaceuticals (NAS:IONS) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Ionis Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms
IONS vs APGE, CYTK, KRYS: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.
Ionis Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -0.90% mean?
Ionis Pharmaceuticals (IONS) has a 3-Year EPS without NRI Growth Rate of -0.90% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ionis Pharmaceuticals and its competitors. According to the industry distribution chart, Ionis Pharmaceuticals ranks #827 out of 1157 companies in the Biotechnology industry, placing it in the top 71.5%.
Is Ionis Pharmaceuticals' 3-Year EPS without NRI Growth Rate too high?
Ionis Pharmaceuticals' current 3-Year EPS without NRI Growth Rate is -0.90%. Based on the distribution chart, Ionis Pharmaceuticals ranks #827 out of 1157 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ionis Pharmaceuticals has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' 3-Year EPS without NRI Growth Rate compare to APGE and CYTK?
According to the Biotechnology industry distribution chart, Ionis Pharmaceuticals ranks #827 out of 1157 companies for 3-Year EPS without NRI Growth Rate. This places Ionis Pharmaceuticals in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 15.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.90, based on 1,157 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ionis Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ionis Pharmaceuticals's current 3-Year EPS without NRI Growth Rate is -0.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (IONS) is currently considered Fairly Valued. The stock's GF Value™ is $48.27, compared to a current price of $44.84 — trading 7.1% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -0.90%. Ionis Pharmaceuticals' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Ionis Pharmaceuticals (IONS), the current 3-Year EPS without NRI Growth Rate is -0.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (IONS) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be undervalued.
The current stock price of $44.84 is trading 7.1% below its estimated GF Value™ of $48.27.
GuruFocus considers Ionis Pharmaceuticals to be Fairly Valued.
Key valuation signals for IONS:
3-Year EPS without NRI Growth Rate: -0.90%
GF Value™: $48.27 vs. price of $44.84 (7.1% below fair value)
No single metric tells the full story. See the IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
69GF Score
Get the complete analysis for IONS
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IONS has been successfully added to your 
